“Based on recent laboratory studies, dronabinol (delta-9-tetrahydrocannabinol) has been shown to reduce cannabis withdrawal symptoms and the subjective effects of marijuana.
Given that agonist agents have been found to be effective for opiate and nicotine dependence, the clinical utility of dronabinol for cannabis dependence is a reasonable approach…
It is clear from the two cases that both patients found the induction onto dronabinol helpful.”
“… there are no effective medications for cannabis dependence. The purpose of this study was to evaluate the safety and efficacy of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol, a naturally occurring pharmacologically active component of marijuana, in treating cannabis dependence.
This is the first trial using an agonist substitution strategy for treatment of cannabis dependence. Dronabinol showed promise, it was well-tolerated, and improved treatment retention and withdrawal symptoms…
In conclusion, agonist substitution pharmacotherapy with dronabinol, a synthetic form of THC, showed promise for treatment of cannabis dependence, reducing withdrawal symptoms and improving retention in treatment…
The trial showed that among adult cannabis-dependent patients, dronabinol was well accepted, with good adherence and few adverse events.”
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154755/
“It has been recently reported that cannabidiol (CBD), a non-psychoactive cannabinoid, is able to kill glioma cells, both in vivo and in vitro, independently of cannabinoid receptor stimulation.
…the present investigation indicates that CBD exerts its antitumoral effects through modulation of the LOX pathway and of the endocannabinoid system…”
“We hypothesized that the prevalence of obesity would be higher in cannabis users than in nonusers… this analysis showed that even if cannabis consumption increases appetite, people using cannabis are less likely to be obese than people who do not use cannabis…
The authors conclude that the prevalence of obesity is lower in cannabis users than in nonusers.”
http://www.ncbi.nlm.nih.gov/pubmed/21868374
http://aje.oxfordjournals.org/content/174/8/929.long
“We estimated the association between legalizing medical marijuana and suicides.
Suicides among men aged 20 through 39 years fell after medical marijuana legalization compared with those in states that did not legalize.
The negative relationship between legalization and suicides among young men is consistent with the hypothesis that marijuana can be used to cope with stressful life events.” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232164/
http://www.ncbi.nlm.nih.gov/pubmed/24432945
http://ajph.aphapublications.org/doi/10.2105/AJPH.2013.301612
“New clinical experience with 9-delta-tetrahydocannabinol (THC) and cannabidiol (CBD) oromucosal spray (Sativex®)…
A randomized, placebo controlled long-term follow-up clinical trial with THC:CBD spray versus placebo demonstrated that it was not associated with cognitive decline, depression or significant mood changes…
THC:CBD oromucosal spray did not adversely influence standard driving ability in patients with moderate to severe MS spasticity…
Findings to date reinforce the efficacy and safety observed in Phase III clinical trials…
Importantly, no additional safety concerns were identified…
Thus, these new data support a positive benefit-risk relationship for THC:CBD oromucosal spray during longer-term use.”
“Experimental in vitro and in vivo evidence, as well as results of clinical studies, have indicated that molecular targets for medications currently available for the treatment of mood disorders, sexually transmitted diseases, metabolic disorders, and diabetes may be active and relevant in thyroid cancer.
For instance, the derivatives of cannabis and an anti-diabetic agent, metformin, are both able to inhibit extracellular signal-regulated protein kinase (ERK), which is commonly activated in thyroid cancer cells.
We present here several examples of well-known medications that have the potential to become new therapeutics for patients with thyroid cancer. Repositioning of established medications for the treatment of thyroid cancer could broaden the scope of current therapeutic strategies. These diverse treatment choices could allow physicians to provide an individualized approach to optimize treatment for patients with thyroid cancer.”
“The cannabis extract nabiximols (Sativex), developed as a multiple sclerosis treatment, offers a potential agonist medication for cannabis withdrawal…
Nabiximols treatment significantly reduced the overall severity of cannabis withdrawal…
The data support further evaluation of nabiximols for management of cannabis dependence and withdrawal in treatment-seeking populations.”
“Non-drug varieties of Cannabis sativa L., collectively known as “hemp”, have been an important source of food, fiber and medicince for thousands of years. The ever-increasing demand for vegetables oils has made it essential to characterize additional vegetable oil through innovative uses of its components…
This study is an important contribution for Cannabis sativa L. valorization as a source of bioactive compounds contributing to research novel applications for hemp seed oil in the food, pharmaceutical, cosmetic and other non-food industries.”
“Acute alcohol drinking induces steatosis, and effective prevention of steatosis can protect liver from progressive damage caused by alcohol… We evaluated whether cannabidiol, which has been reported to function as an antioxidant, can protect the liver from alcohol-generated oxidative stress induced steatosis.
Cannabidiol can prevent acute alcohol induced liver steatosis in mice… Importantly, cannabidiol can prevent the decrease of autophagy induced by alcohol.
In conclusion, these results show that cannabidiol protects mouse liver from acute alcohol induced steatosis through multiple mechanisms including attenuation of alcohol-mediated oxidative stress, prevention of JNK MAPK activation, and increasing autophagy.”